Australian Clinical Labs Ltd ACL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- A$2.49
- Day Range
- A$2.45–2.50
- 52-Week Range
- A$2.26–3.69
- Bid/Ask
- A$2.45 / A$2.50
- Market Cap
- A$496.51 Mil
- Volume/Avg
- 246,118 / 526,605
Key Statistics
- Price/Earnings (Normalized)
- 23.59
- Price/Sales
- 0.73
- Dividend Yield (Trailing)
- 4.06%
- Dividend Yield (Forward)
- 4.06%
- Total Yield
- 4.19%
Company Profile
Australian Clinical Labs, or ACL, is Australia’s third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well-established in the states of Western Australia, South Australia, Victoria and the Northern Territory.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- —
- Website
- https://www.clinicallabs.com.au
Competitors
Valuation
|
Metric
|
ACL
|
HLS
|
SHL
|
|---|---|---|---|
Price/Earnings (Normalized) | 23.59 | 2.49 | 24.41 |
Price/Book Value | 2.93 | 0.87 | 1.63 |
Price/Sales | 0.73 | 0.45 | 1.49 |
Price/Cash Flow | 3.15 | 2.69 | 10.96 |
Price/Earnings
ACL
HLS
SHL
Financial Strength
|
Metric
|
ACL
|
HLS
|
SHL
|
|---|---|---|---|
Quick Ratio | 0.52 | 0.44 | 0.78 |
Current Ratio | 0.66 | 0.53 | 0.94 |
Interest Coverage | 2.44 | −13.26 | 5.95 |
Quick Ratio
ACL
HLS
SHL
Profitability
|
Metric
|
ACL
|
HLS
|
SHL
|
|---|---|---|---|
Return on Assets (Normalized) | 3.13% | 0.10% | 4.07% |
Return on Equity (Normalized) | 10.73% | 0.23% | 7.01% |
Return on Invested Capital (Normalized) | 5.84% | 2.27% | 4.52% |
Return on Assets
ACL
HLS
SHL
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Hxdvqfykh | Chm | $209.3 Bil | |
DHR
| Danaher Corp | Gncxgtrdg | Ngyhkm | $182.1 Bil | |
IQV
| IQVIA Holdings Inc | Vhwrhkz | Vflcm | $43.4 Bil | |
IDXX
| IDEXX Laboratories Inc | Bgkmscnr | Zcvdqxh | $41.0 Bil | |
A
| Agilent Technologies Inc | Mlnbpmdk | Vcyc | $40.3 Bil | |
MTD
| Mettler-Toledo International Inc | Fwqwyjtgj | Zslnfny | $26.4 Bil | |
ICLR
| Icon PLC | Mrrkgsjch | Fynltz | $24.8 Bil | |
ILMN
| Illumina Inc | Sxrxlrb | Nzqhjp | $19.3 Bil | |
WAT
| Waters Corp | Hsqkktvkpd | Rsvv | $18.3 Bil | |
LH
| Laboratory Corp of America Holdings | Xcbyrrlsr | Gfmhst | $17.5 Bil |